MARKET

GKOS

GKOS

Glaukos Corp
NYSE
140.67
+4.97
+3.66%
Opening 15:58 12/06 EST
OPEN
137.35
PREV CLOSE
135.70
HIGH
142.80
LOW
137.32
VOLUME
630.57K
TURNOVER
--
52 WEEK HIGH
146.86
52 WEEK LOW
59.58
MARKET CAP
7.76B
P/E (TTM)
-47.4964
1D
5D
1M
3M
1Y
5Y
1D
Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar?
NASDAQ · 2d ago
How Is The Market Feeling About Glaukos?
Benzinga · 3d ago
Revenues Tell The Story For Glaukos Corporation (NYSE:GKOS)
Simply Wall St · 3d ago
Morgan Stanley bullish on medtech in 2025, upgrades 5 stocks
Seeking Alpha · 3d ago
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Benzinga · 4d ago
Glaukos Is Maintained at Buy by Stifel
Dow Jones · 4d ago
Stifel Maintains Buy on Glaukos, Raises Price Target to $153
Benzinga · 4d ago
Tesla upgraded, Autodesk initiated: Wall Street’s top analyst calls
TipRanks · 4d ago
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.